Leber hereditary optic neuropathy: bridging the translational gap
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
PURPOSE OF REVIEW: Leber hereditary optic neuropathy (LHON) is the most common primary mitochondrial DNA (mtDNA) genetic disorder in the population. We address the clinical evolution of the disease, the secondary etiological factors that could contribute to visual loss, and the challenging task of developing effective treatments. RECENT FINDINGS: LHON is characterized by a preclinical phase that reflects retinal ganglion cell (RGC) dysfunction before rapid visual deterioration ensues. Children can present atypically with slowly progressive visual loss or an insidious/subclinical onset that frequently results in considerable diagnostic delays. The LHON mtDNA mutation is not sufficient on its own to precipitate RGC loss and the current body of evidence supports a role for smoking and estrogen levels influencing disease conversion. Clinical trials are currently investigating the efficacy of adeno-associated viral vectors-based gene therapy approaches for patients carrying the m.11778G>A mutation. Mitochondrial replacement therapy is being developed as a reproductive option to prevent the maternal transmission of pathogenic mtDNA mutations. SUMMARY: LHON is phenotypically more heterogeneous than previously considered and a complex interplay of genetic, environmental and hormonal factors modulates the risk of a LHON carrier losing vision. Advances in disease modelling, drug screening and genetic engineering offer promising avenues for therapeutic breakthroughs in LHON.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mitochondrial DNA mutation associated with Leber’s hereditary optic neuropathy
Wallace, D. C., Singh, G., Lott, M. T., Hodge, J. A., Schurr, T. G., Lezza, A. M. S., Elsas, L. J., & Nikoskelainen, E. K. (1988) · Science · doi:10.1126/science.3201231 · Cited by 2,440
Induced pluripotent stem cell technology: a decade of progress.
Shi, Y., Inoue, H., Wu, J. C., & Yamanaka, S. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.245 · Cited by 1,525
Vitamin B 3 modulates mitochondrial vulnerability and prevents glaucoma in aged mice
Williams, P. A., Harder, J. M., Foxworth, N. E., Cochran, K. E., Philip, V. M., Porciatti, V., Smithies, O., & John, S. W. M. (2017) · Science · doi:10.1126/science.aal0092 · Cited by 617
A randomized placebo-controlled trial of idebenone in Leber’s hereditary optic neuropathy.
Klopstock, T., Yu-Wai-Man, P., Dimitriadis, K., Rouleau, J., Heck, S., Bailie, M., Atawan, A., Chattopadhyay, S., Schubert, M., Garip, A., et al. (2011) · Brain · doi:10.1093/brain/awr170 · Cited by 578
Self-citationGene Therapy for Leber Hereditary Optic Neuropathy
Feuer, W. J., Schiffman, J. C., Davis, J. L., Porciatti, V., Gonzalez, P., Koilkonda, R. D., Yuan, H., Lalwani, A., Lam, B. L., & Guy, J. (2016) · Ophthalmology · doi:10.1016/j.ophtha.2015.10.025 · Cited by 230
Efficacy and Safety of rAAV2-ND4 Treatment for Leber’s Hereditary Optic Neuropathy
Wan, X., Pei, H., Zhao, M.-J., Yang, S., Hu, W.-K., He, H., Ma, S.-Q., Zhang, G., Dong, X.-Y., Chen, C., et al. (2016) · Scientific Reports · doi:10.1038/srep21587 · Cited by 182
A neurodegenerative perspective on mitochondrial optic neuropathies
Yu-Wai-Man, P., Votruba, M., Burté, F., La Morgia, C., Barboni, P., & Carelli, V. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1625-2 · Cited by 176
Self-citationLong-term outcomes of gene therapy for the treatment of Leber’s hereditary optic neuropathy
Yang, S., Ma, S.-Q., Wan, X., He, H., Pei, H., Zhao, M.-J., Chen, C., Wang, D.-W., Dong, X.-Y., Yuan, J.-J., et al. (2016) · eBioMedicine · doi:10.1016/j.ebiom.2016.07.002 · Cited by 139
Cited by
Mitochondrial disorders of the OXPHOS system
Fernandez‐Vizarra, E., & Zeviani, M. (2021) · FEBS Letters · doi:10.1002/1873-3468.13995 · Cited by 305
Roska, B., & Sahel, J.-A. (2018) · Nature · doi:10.1038/s41586-018-0076-4 · Cited by 161
Treatment strategies for Leber hereditary optic neuropathy
Jurkute, N., Harvey, J., & Yu-Wai-Man, P. (2019) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000646 · Cited by 38
“Mitochondrial Neuroprotection – Idebenone Idebenone is a synthetic, short-chain analogue of ubiquinone, which is responsible for shuttling electrons from complexes I and II directly to complex III [13].”
BackgroundInfluentialSelf-citationLiu, Y., Eastwood, J. D., Alba, D. E., Velmurugan, S., Sun, N., Porciatti, V., Lee, R. K., Hauswirth, W. W., Guy, J., & Yu, H. (2022) · Gene Therapy · doi:10.1038/s41434-022-00333-6 · Cited by 19
Mitochondrial Transfer of the Mutant Human ND6T14484C Gene Causes Visual Loss and Optic Neuropathy
Yu, H., Sant, D. W., Wang, G., & Guy, J. (2020) · Translational Vision Science & Technology · doi:10.1167/tvst.9.11.1 · Cited by 13
Metadata
- Authors
- Jurkute, N., & Yu-Wai-Man, P.
- Venue
- Current Opinion in Ophthalmology
- Published
- 2017-09
- Volume
- 28
- Issue
- 5
- Pages
- 403-409
- ISSN
- 1040-8738 (ISSN-L)
- OpenAlex
- W2724870532
- Cited by
- 70
- References
- 8
- FWCI
- 2.91
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Leber hereditary optic neuropathy: bridging the translational gap. https://app.cochat.ai/papers/10.1097/icu.0000000000000410
- The paper
- Jurkute, N., & Yu-Wai-Man, P. (2017). Leber hereditary optic neuropathy: bridging the translational gap. Current Opinion in Ophthalmology. https://doi.org/10.1097/icu.0000000000000410
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.